Alzheimer Disease, Dementia, Vascular, Mild Cognitive Impairment
Conditions
Keywords
Dementia, Alzheimer's disease, mild cognitive impairment
Brief summary
Mild cognitive impairment (MCI) is believed to be the early stage of dementia. The investigators assume that some psychological and imaging risks may predict the conversion. In the current longitudinal study, psychological and imaging data of people with MCI will be obtained at baseline, and will be followed at 26 weeks and 52 weeks. The predictors will be found in comparison with controls.
Detailed description
MCI increases the risk of later developing dementia. About 10-15% of the amnestic form of mild cognitive impairment will progress to Alzheimer's disease in one year. But some people with MCI never get worse. Others with MCI later have test results that return to normal for their age and education. To develop a new drug for the prevention of dementia(dementia due to Alzheimer's disease or vascular dementia), investigators need a sensitive and specific tool for recognizing patients who will converse to dementia. The investigators want to establish an operational diagnostic criteria instead of a descriptive criteria for mild cognitive impairment.
Interventions
None listed
Sponsors
Dongzhimen Hospital, Beijing
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
40 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
* complaint about cognitive decline compared to previous performance * objective cognitive impairment in one or more cognitive domains for age * preservation of independence in functional abilities * Mini-Mental State Examination(MMSE) scores between 24 and 30 * a Clinical Dementia Rating(CDR) score of 0.5
Exclusion criteria
* dementia * patient with any following disease: Parkinson's disease, multiple system atrophy, normal pressure hydrocephalus, progressive supranuclear palsy, subarachnoid hemorrhage, brain neoplasms, Huntington disease, epilepsy * depression(HAMD \>7) or psychosis * uncontrolled severe medical conditions(i.e., acute heart failure, renal insufficiency) * current treatment with benzodiazepines, antidepressants, antipsychotics, or other medications with significant psychotropic or central cholinergic effects * abnormal thyroid, low vitamin B12 level or low folic acid level * patient with visual and auditory disorders can't cooperate with neuropsychological assessment * patient can't cooperate with following up * informed consent is not obtained
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Rate of conversion to dementia | At baseline, 26 weeks, and 52 weeks. |
Secondary
| Measure | Time frame |
|---|---|
| Immediate and delayed story recall | At baseline, 26 weeks, and 52 weeks |
| Clock Drawing Test(CDT) | At baseline, 26 weeks, and 52 weeks |
| Boston Naming Test | At baseline, 26 weeks, and 52 weeks |
| Mini-Mental State Examination | At baseline, 26 weeks, and 52 weeks |
| Trail Making Test(TMT) | At baseline, 26 weeks, and 52 weeks |
| Hopkins Verbal Learning Test(HVLT) | At baseline, 26 weeks, and 52 weeks |
| Verbal Category Fluency Test(animals) | At baseline, 26 weeks, and 52 weeks |
Countries
China
Outcome results
None listed